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A B S T R A C T
Anti-HPA-1a-antibodies are the main cause of fetal and neonatal alloimmune thrombocytopenia (FNAIT) which
may result in intracranial hemorrhage (ICH) and death among fetuses and newborns. Advances in understanding
the pathogenesis of FNAIT and proof of concept for prophylaxis to prevent immunization suggest that devel-
opment of hyperimmune anti-HPA-1a IgG aimed at preventing immunization against HPA-1a and FNAIT is
feasible. Anti-HPA-1a IgG can be obtained either by isolating immunoglobulin from already-immunized women
or by development of monoclonal anti-HPA-1a antibodies.
Here we discuss recent advances that may lead to the development of a prenatal and postnatal prophylactic
treatment for the prevention of HPA-1a-associated FNAIT and life-threatening FNAIT-induced complications.
1. Introduction
Platelet integrins are carriers for multiallelic determinants. These
antigens are commonly referred to as platelet specific alloantigens or
human platelet antigens (HPAs) despite the fact that some of them are
present to a lesser extent on other types of cells such as endothelial
cells, lymphocytes, and placental trophoblasts. These platelet antigens
play an important role in immune-mediated platelet disorders.
Alloimmunization mainly occurs in relation to pregnancy or platelet
transfusion. Fetal and neonatal alloimmune thrombocytopenia (FNAIT)
is suspected when a fetus or newborn is found to have thrombocyto-
penia, either incidentally or because of unexpected bleeding signs and
symptoms. FNAIT is confirmed after identification of maternal platelet
specific antibodies against fetal antigens (not expressed in the mother).
In Caucasians, anti-HPA-1a antibodies are of particular interest because
they account for about 85 % of all cases of severe FNAIT [1]. Severe
anti-HPA-1a antibody-induced FNAIT occurs in approximately one of
1800 pregnancies [2]. Intrauterine death or neurological sequelae have
been reported to occur in approximately one per 10 000 newborns [3].
In Europe, this translates into approximately 500 infants per year and in
the USA approximately 400 infants per year.
Prophylactic treatment was previously not considered for FNAIT
because it was generally believed that immunization against HPA-1a
mainly occurred during the first incompatible pregnancy. Results from
two large prospective clinical studies indicated however, that the ma-
jority of HPA-1a immunizations had occurred in connection with de-
livery in a previous pregnancy [4,5]. This was confirmed in a large
Norwegian prospective clinical trial [2]. In the Norwegian study it was
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shown that 75 % of all cases of HPA-1a alloimmunization occurred in
relation to delivery rather than during pregnancy [6]. The remaining 25
% of cases of alloimmunization occurred during an incompatible
pregnancy. The realization that alloimmunization mainly occurs after
delivery suggested that HPA-1a alloimmunization may be prevented in
a manner similar to the prevention of RhD immunization and hemolytic
disease of fetus and newborn (HDFN) [7]. For more than 5 decades,
anti-D immunoglobulin has successfully been used to prevent HDFN.
Before the implementation of prophylaxis against anti-D, approximately
15 % of RhD negative women became anti-D immunized, which de-
clined to 1 % after the introduction of post-partum prophylaxis and 0.2
% when antenatal prophylaxis was added [8].
Heyu Ni and co-workers have developed a murine model, using β3
integrin (GPIIIa) deficient mice (β3-/-), that recapitulate the clinical
manifestations of FNAIT [9]. The availability of an animal model of
FNAIT made it possible to investigate if prophylactic treatment is fea-
sible to prevent thrombocytopenia and bleeding symptoms caused by
anti-platelet antibodies. This model was applied in a study, where fe-
male β3 integrin (GPIIIa) deficient mice were transfused with β3 po-
sitive platelets, with or without a separate injection of prophylaxis
(anti-β3 antibodies) to simulate fetal-maternal bleeding (FMB). Two
weeks later, the females were bred with WT BALB/c mice (β3 in-
compatible pregnancy). Pup platelet counts, birth weight and signs of
bleeding were recorded within 24 h after delivery. This proof of concept
study successfully demonstrated that prophylactic treatment with an
anti-β3 antibody could prevent both maternal immunization and
thrombocytopenia and bleeding complications in the pubs [10].
Although the majority of HPA-1a immunizations appear to occur
during delivery, the prospective screening studies [2,4,5] reported se-
vere FNAIT cases also in first pregnancies. Recently, a study by Jin et al.
[11] reported that 60 % of affected FNAIT pregnancies were first
pregnancies including 71 % of first pregnancies complicated by fetal
ICH. The ICH’s occurred in the second half of the second trimester and
early third trimester in many of the cases. Results from this retro-
spective study, that included a selected group of women, still needs to
be confirmed by a prospective study. However, this finding demon-
strates that in order to prevent all severe FNAIT cases, both antenatal
and postnatal prophylaxis is required.
In order to identify pregnant women at risk for immunization, and
in need of prophylactic treatment, pregnant women need to be HPA-1a
typed early in pregnancy. This could be done by screening for HPA-1a
in the same sample used for RhD typing. Both phenotyping and geno-
typing assays can be configured for high through-put screening assays
[12,13]. Further stratification, to identify high risk pregnancy may also
be included in a screening program. Such a stratification should include
HLA-DRB3*01:01 typing, since the risk of HPA-1a-immunisation is 25
times higher in HLA-DRB3*01:01 positive women as opposed to women
lacking this HLA allele [14], and because the risk of severe neonatal
outcome is very low in those few HLA-DRB3*01:01 negative women
who become HPA-1a-immunized [15].
In the current review we discuss recent advances that may lead to
the development of a prenatal and postnatal prophylactic treatment for
the prevention of HPA-1a-associated FNAIT and life-threatening FNAIT-
induced complications.
2. Collection of plasma and manufacture of hyperimmune anti-
HPA-1a IgG, NAITgam
In 2012 the EU-funded PROFNAIT project was established with the
aim of developing a hyperimmune anti-HPA-1a IgG prophylaxis for
prevention of HPA-1a-immunization and FNAIT. The PROFNAIT con-
sortium consisted of eleven Northern European hospitals, blood banks
and companies with experience and key expertise in FNAIT and drug
development (Fig. 1). In addition, strong collaboration was entered
with NAITbabies (www.NAITbabies.com), a patient organization run by
families affected by FNAIT, several US plasma centers as well as the
manufacturing company Emergent BioSolutions, Winnipeg, Canada.
A total of 86 female donors were identified in Germany, Norway
and Sweden. The majority of these donors were FNAIT mothers
(n= 69) referred to the program by their doctors, the rest were iden-
tified by screening of HPA-1a negative donors at German Red Cross.
Utilization of the donated EU plasma was highly desirable, but chal-
lenging since only a few FDA-compliant manufacturers allowed EU
plasma into their facilities, including, Emergent BioSolutions. For this
reason, plasma collection was initiated in the US. NAITbabies en-
couraged their HPA-1a-immunized members to sign up as plasma do-
nors on PROFNAIT’s webpage, as did centers involved in the care of
affected women. In the US more than 100 alloimmunized women vo-
lunteered to donate plasma. An informed consent was obtained from all
recruited donors. In addition, a high number of female plasma donors
were screened for anti-HPA-1a antibodies and enrolled in the NAITgam
donation program.
For a donor to be included in the NATIgam screening program, the
donor had to be HPA-1bb and have anti-HPA-1a antibody level> 10
IU/mL. Donors with anti-Human Neutrophil Antibodies (HNA), platelet
activating HPA-1a antibodies or alloantibodies towards red blood cells
(RBC) were excluded. One European donor had anti-HNA antibodies
and platelet activating HPA-1a antibodies and was excluded from the
donation program. None of the female donors had alloantibodies
against RBC. The anti-HPA 1a antibody level in the individual donors
fell to approximately 50 % of the starting level due to frequent dona-
tions. Mean anti-HPA-1a antibody level in the whole pool was 40 IU/
mL (SEM=7.8 IU/mL). Thus, the final plasma pool used for manu-
facture of NAITgam had no alloantibodies against RBC, no anti-HNA or
platelet activating HPA-1a antibodies. However, low levels of anti-HLA
I (titer 1) were detected.
The glycosylation profile of the IgG antibody’s Fc fragment, parti-
cularly the absence of core fucosylation, which is normally present in
all IgG, is known to be essential for Fc receptor-mediated activity
[16–18]. Kapur et al. have recently demonstrated that HPA-1a IgG
antibodies in immunized women have very low levels of fucose as
compared with total IgG. Similarly, in RhD-immunized women, the IgG
antibodies against the RhD antigen have also low levels of fucose,
which is also reflected in the polyclonal prophylactic anti-D drug pro-
ducts [19–21]. The level of anti-HPA-1a IgG1 fucosylation in FNAIT
pregnancies has been shown to be associated with the platelet counts in
the new-born [21]. A follow-up study showed that this alteration in
fucosylation of anti-HPA-1a seems to occur early in the immune re-
sponse (first/second pregnancy) and then be extremely stable over time
[22].
The glycosylation profiles of the donors from HPA-1a-immunized
women were investigated (both EU and US donors), and we found no
differences in fucosylation patterns between anti-HPA-1a IgG1 isolated
from donors identified by screening (unknown FNAIT history) com-
pared to anti-HPA-1a isolated from donors who have given birth to
children with clinical bleeding symptoms (FNAIT mothers). Both
groups had a decreased fucosylation in the total IgG (84 %) compared
to the healthy population (94 %) (Table 1).
All plasma was collected and tested in compliance with FDA and
EMA guidelines aimed for production of NAITgam both for the
European and US markets. In June 2019, Rallybio, a US biotech com-
pany dedicated to identify and accelerate development of life-trans-
forming therapies for patients with severe and rare disorders, acquired
the orphan drug program for NAITgam from Prophylix AS, and will
proceed with safety and dose finding clinical phase I/II trials in 2020.
NAITgam was manufactured by the same process as used for by
Emergent BioSolution for production of their intravenous im-
munoglobulin (IVIg) products. Thus, NAITgam will be similar to other
hyperimmune products manufactured by Emergent BioSolution, except
for the antibody specificity. This means that one would expect that
these hyperimmune drug products would be representative for the
safety profile of NAITgam. Broad experience in humans with
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intravenous administration of IgG drug products has demonstrated a
favorable safety profile of this class of products As an example,
WinRho® (IV anti-D) has been on the market for more than 30 years
first for the prevention of HDFN and later for treatment of immune
thrombocytopenia (ITP) [23].
The World Health Organization (WHO) has determined that 125 IU
anti-D IgG is the dose needed to prevent sensitization derived from one
mL of fetal whole blood during pregnancy [24]. A standard dose of
Fig. 1. The PROFNAIT Consortium.
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1500 IU would generally suppress an immunization after FMB of up to
30mL of fetal whole blood [25,26]. It is worthwhile mentioning that
even though a 30mL FMB is used as a guidance for optimal prevention
of maternal immunization, it has been estimated that FMB, at the time
of delivery, is limited to a maximum of 1mL fetal red cells in 98 % of
women [27]. Further, from anti-D studies we know that it is not ne-
cessary to obtain full saturation of the antigenic sites to obtain anti-
body-mediated immune suppression (AMIS) [28], which most likely
could also be the case for anti-HPA-1a. In vitro studies have shown that
approximately 0.5 IU/ml anti-HPA 1a antibodies saturate approxi-
mately 10 % of HPA 1a on HPA 1ab platelets. In an in vivo situation this
would be equal to a dose of 2000 IU. The optimal dose of NAITgam, in
order to induce rapid clearance, will be determined in a clinical phase II
trial in 2020.
3. Possible mechanism of action
Immunization against HPA-1a occurs when a woman is exposed to
fetal platelet antigens, most probably due to a FMB during gestation or
at delivery. The risk of FMB is low during the first two trimesters but
increases in cases of early spontaneous or provoked abortion. During
last trimester, FMB has been shown to occur in approximately 6–7 % of
all pregnancies [29]. Fetal blood is commonly found in maternal cir-
culation and detected in around 96 % of normal deliveries after delivery
[30]. It has also been speculated if microvesicles due to shedding of
trophoblasts could be an alternative source for immunization against
HPA-1a [31] or that immunization could be caused by invasive tro-
phoblast cells that express integrin β3, which harbor the HPA-1a an-
tigen. Maternal anti-HPA-1a antibodies directed against fetal HPA-1a
cross the placenta and bind fetal platelets, which in turn are removed by
splenic macrophages through antibody mediated phagocytosis [32]
leaving the fetus and/or newborn thrombocytopenic and at risk for
bleeding. Additionally, maternal anti-HPA-1a antibodies binding to
megakaryocytes are believed to increase the severity of the thrombo-
cytopenia [33] and binding to developing endothelial cells have also
been suggested to result in bleeding in the fetus and newborn [34].
The mechanisms of hyperimmune anti-HPA-1a to prevent im-
munization against HPA-1a would likely be analogous to the proposed
mechanisms of hyperimmune anti-D. Explanations for AMIS have been
discussed for many years [35], but AMIS is still not fully understood.
One possible mechanism is that that anti-D-sensitized fetal RBC will be
subject to phagocytosis by the maternal mononuclear phagocytic
system before the mother starts an antibody response. Accordingly, it is
believed that anti-HPA-1a antibodies, when administered to HPA-1a
negative women, will sensitize fetal platelets and remove fetal HPA-1a
positive platelets, thereby preventing maternal HPA-1a-immunization
and FNAIT. Several studies supporting this hypothesis have shown that
administration of antibodies against RBC or platelets lead to rapid
clearance of the targeted cells [36–39]. Ghevaert et al. showed that
binding of a monoclonal antibody specific to HPA-1a cleared HPA-1ab
positive platelets within 2 h. However, alternative mechanisms, such as
(partial) epitope masking, antigen-modulation and/or co-engagement
of the B cell receptor with the inhibitory Fc-receptor FcγRIIb can’t be
excluded [40].
The HPA-1a antigen is located on the β3 integrin. Platelets express
both αIIbβ3 (fibrinogen receptor) and αvβ3 (vitronectin receptor). In
addition, αvβ3 is present on both endothelial cells [41,42] and tro-
phoblasts [43]. Studies on maternal antibody response against HPA-1a
have shown that the immunoglobulins are heterogeneous and targeted
binding sites differ from one individual to another [34,44–46]. It has
been shown that some anti-HPA-1a antibodies bind to an epitope
comprised solely of the amino-terminus on β3, while others bind to
more complex determinants involving both the β3 and αIIb integrins
[45,46]. In addition, Santoso and co-workers [34] have identified a
third sub-type of HPA-1a antibodies that react with the αvβ3 integrin
complex. This sub-type of anti-HPA-1a was mainly present in sera from
women who had given birth to children with ICH, indicating that the
anti-HPA-1a binding pattern is important for clinical outcome. The fact
that there are individual differences in the anti-HPA-1a antibody pat-
tern might also be an important aspect in effect of the prophylaxis, and
support the idea that hyperimmune anti-HPA-1a prophylaxis generated
from several donors, to ensure a broad binding pattern towards HPA-1a,
could be important.
An alternative to plasma derived hyperimmune anti-HPA-1a pro-
phylaxis could be the use of a monoclonal anti-HPA-1a antibody. The
advantages of monoclonal antibodies are their homogeneity and con-
sistency. However, the monospecificity of such antibodies could limit
their usefulness, as binding to a single HPA-1a epitope may not suffi-
ciently deliver the prophylactic preventive function. Polyclonal anti-
bodies, on the other hand, are heterogeneous and recognize several
antigenic epitopes. The heterogeneous nature of polyclonal antibodies,
however, also makes them more prone to batch-to-batch variability, but
this can largely be overcome using sizable pools of donors, which has a
proven to be a successful strategy for RhD-prophylactic products.
Another key advantage of using a monoclonal antibody is that once the
desired production systems has been established, anti-HPA-1a IgG can
be generated as a constant and renewable resource. Further, the con-
centration and purity levels of specific antibodies can be made higher in
drug products based on monoclonal antibodies; typically monoclonal
antibodies generated in specialized cell cultures are frequently 10-fold
higher in concentration than polyclonal antibodies, and of much higher
purity [47]. Many of the disadvantages of monoclonal antibodies may
possible be overcome by pooling multiple clones that recognize dif-
ferent HPA-1a epitopes. However, it is difficult, time consuming and
expensive to identify multiple monoclonal antibodies of a separate,
desired specificity.
A fully human monoclonal anti-HPA-1a antibody has been gener-
ated from an immunized woman who had a child with FNAIT. This
antibody, which binds both to the αvβ3 integrin as well as the αIIbβ3
integrin [48], the two different HPA-1a epitopes known to be important
for severe FNAIT [34,46], is a good candidate for future prophylaxis of
HPA-1a-immunization and FNAIT.
4. Conclusion
Currently there is a compelling need to develop new effective
therapeutic treatments to prevent FNAIT and FNAIT induced compli-
cations. Collecting plasma and manufacturing of the first GMP batch of
hyperimmune anti-HPA-1a IgG is a great step forward in the fight
against FNAIT. Prophylactic treatment has great potential and may be a
clinical reality in the near future. Prenatal prophylactic treatment
would be superior to a single postpartum treatment, since immuniza-
tion and complications due to severe FNAIT would be prevented also in
first pregnancies.
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Table 1
Source and pool plasma characteristics.
Hyperimmune plasma for NAITgam production
Total Volume, (L) 84 (EU), 515 (US)
Individual anti-HPA-1a antibody level, range (IU/ml) 2-143
Percentage of fucosylated total IgG (n=81), mean % (SEM) 84 (9)
Percentage of fucosylated anti-HPA-1a IgG (n= 81), mean
% (SEM)
37 (4)
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